Tongue neurostimulation for snoring and mild obstructive sleep apnea
Customize your policy alerts
Sign up for AmeriHealth Caritas Policy CCP.1559 alerts
Get alerted when Policy CCP.1559 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of removable daytime tongue neurostimulation devices (e.g., eXciteOSA) for adults with primary snoring or mild obstructive sleep apnea and guides AmeriHealth Caritas medical necessity determinations for these devices.
No material clinical or coverage changes in this revision.
Coverage Determination and Rationale
Not medically necessary
Coverage determination
Policy statement
Tongue neurostimulation devices and related procedures for the treatment of primary snoring or mild obstructive sleep apnea are not medically necessary. This exclusion applies to removable intraoral neuromuscular electrical stimulation devices (including eXciteOSA) and any associated services when used to treat snoring or mild OSA because the therapy is considered investigational and not clinically proven.
Tongue neurostimulation, including the eXciteOSA system, is considered investigational / not clinically proven for the treatment of snoring or mild obstructive sleep apnea. Because available evidence does not establish clinical benefit for these indications, use of these devices is not medically necessary.
Codes and Clinical Thresholds
| E0490 | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote. |
| E0491 | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply. |
| E0492 | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application. |
| E0493 | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply. |
| A9279 | Monitoring feature/device, stand-alone or integrated, any type, includes all accessories, components and electronics, not otherwise classified. |
Provider Guidance, Billing, and Documentation
Device coding and coverage stance for E0490–E0493, A9279
Use of tongue neurostimulation devices is considered investigational/not medically necessary; claims submitted with HCPCS codes E0490–E0493 or A9279 should be processed consistent with the policy's noncoverage stance (denial or prior authorization per plan procedures).
Consider alternative therapies before tongue neurostimulation
The policy notes alternative, standard clinical approaches that should be considered instead of tongue neurostimulation: lifestyle measures, mandibular advancement devices, positive airway pressure therapy, and surgery, with choice driven by disease severity, anatomy, symptoms, and tolerance.
- Lifestyle measures (weight loss, sleep hygiene, alcohol/caffeine avoidance)
- Mandibular advancement devices
- Positive airway pressure therapy
- Surgical procedures when appropriate
Documentation expectations per FDA labeling and clinical guidance
Document device labeling and clinical assessments as described in the FDA labeling: prescribe per labeling (adult patients ≥18 years), record dental assessment before use, plan for repeat sleep testing when indicated, and arrange regular follow-up with dental and sleep health professionals.
- Confirm patient meets indicated population per labeling (adults age 18 years or older).
- Document prescription intent and FDA labeling references (awake use only).
- Document dental assessment prior to device use and any identified contraindications (e.g., mouth ulceration, intraoral metallic objects).
- Plan and document repeat sleep testing if AHI ≥15 is suspected or as clinically indicated.
- Record scheduled regular follow-up with dental and sleep health professionals.
Denial risk for tongue neurostimulation claims (including eXciteOSA)
Claims for tongue neurostimulation (including eXciteOSA) for snoring or mild obstructive sleep apnea are not medically necessary and may be denied; submitters should expect denials for these services per the coverage policy.
- Denial applies to device use and related procedures for treatment of snoring or mild OSA.
- Providers should not expect payment for these services under this policy.
Background
Tongue neurostimulation is a removable daytime intraoral neuromuscular electrical stimulation therapy that delivers stimulation to tongue muscles to reduce posterior tongue relaxation and improve upper airway patency during sleep. The therapy (as marketed in systems such as eXciteOSA) is intended to train or increase tongue muscle tone with the goal of reducing snoring and mild obstructive sleep apnea; however, this policy finds the approach investigational and not medically necessary for those indications.
Definitions and Device Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.